Lazari Capital Management Inc. Sells 1,000 Shares of Pfizer Inc. (NYSE:PFE)

Lazari Capital Management Inc. lessened its position in Pfizer Inc. (NYSE:PFE) by 5.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 18,349 shares of the biopharmaceutical company’s stock after selling 1,000 shares during the period. Lazari Capital Management Inc.’s holdings in Pfizer were worth $528,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in PFE. Advisor OS LLC boosted its stake in Pfizer by 1.0% during the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after purchasing an additional 365 shares during the last quarter. Safeguard Investment Advisory Group LLC boosted its position in shares of Pfizer by 3.9% during the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 371 shares during the last quarter. King Wealth Management Group boosted its position in shares of Pfizer by 2.4% during the 4th quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 388 shares during the last quarter. Advance Capital Management Inc. boosted its position in shares of Pfizer by 4.0% during the 4th quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock valued at $293,000 after acquiring an additional 391 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC boosted its position in shares of Pfizer by 1.4% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 28,952 shares of the biopharmaceutical company’s stock valued at $834,000 after acquiring an additional 396 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. BMO Capital Markets restated an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Morgan Stanley boosted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $35.86.

Pfizer Stock Performance

NYSE:PFE traded down $0.12 on Friday, reaching $27.53. 29,461,921 shares of the company’s stock were exchanged, compared to its average volume of 32,712,070. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The business has a fifty day moving average of $27.56 and a 200-day moving average of $27.78. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.36.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.23 earnings per share. Equities analysts predict that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 10th were issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.10%. The ex-dividend date of this dividend was Thursday, May 9th. Pfizer’s payout ratio is -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.